EPFL spin-off Aleva Neurotherapeutics has just raised 13 million dollars in its fourth fund-raising round. The company, based at EPFL’s Innovation Park, will use the proceeds to obtain EU market certification for its new deep brain stimulation (DBS) system.
Themes
Startups and Industry, Microengineering, Neuroscience, Research and Tech Transfer